Tag Archives: valley of death

Making it Personal

making-it-personal copy

The “valley of death” between drug discovery and the development and provision of therapy is a huge issue in biotech. Recent news, however, highlights valiant entrepreneurs who look at the chasm and are building bridges to cross it. One of these is Ilan Ganot whose son, Eytani, was diagnosed with Duchenne muscular dystrophy (DMD) at the age of two years old. The ex-hedge fund banker at JPMorgan Chase & Co quit his job in London, Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Commercialization and Job Creation in the Biotechnology Sector

Doug Crawford

It’s tough presenting programs on technology transfer because so much has already been said that it’s hard to find something new. However, that was not a problem this week in San Francisco at the BIO Technology Transfer Symposium. The Symposium began with an overview of the efforts by the Obama Administration to spur innovation including funding macro and micro grants to encourage the development of regional technology clusters, and proof of concept centers to help Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Debunking the Myth: ‘Gene Patents’ are not necessary for healthcare innovation.

Myth: ‘Gene Patents’ are not necessary for health care innovation. Facts: Patents on DNA preparations or sequences are often the first patents upon which a later technology platform or portfolio is built.  These patents are often in-licensed from universities by small start-up companies for the purpose of additional R&D, evidencing that the public/non-profit university sector cannot bear alone the cost of development of these inventions into useful products. It is precisely these types of early-stage companies Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

BIO Pacific Rim Summit: Status of Cellulosic Ethanol Commercialization

Qteros, ZeaChem and Verenium presented updates on their efforts to bring three unique cellulosic ethanol processes to commercial status. Qteros CTO Kevin Gray described how the company’s Q Microbe™ (Clostridium phytofermentans) enables a single step (consolidated bioprocessing) conversion and fermentation process for fuels. This approach can save as much as 40 percent in production costs. Qteros is currently scaling its technology up for a 100 liter laboratory bioreactor. ZeaChem President and CEO Jim Imbler outlined Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,